reports
Charles River Launches Viral Vector Reference Materials to Streamline ...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its reference materials for adeno associated virus (AAV) and lentiviral vector (LVV) portfolio, designed to streamline Cell and Gene Therapy (CGT) research and development as it scales to Good Manufacturing Practice- (GMP) quality. Moving towards a gold standard for reference materials, Charles River is introducing six AAV reference material serotypes, offering superior and capsid ratios and high vector genome concentration (GC/mL), plus five products, available wi...
Moody's Ratings affirms Charles River's Ba1 CFR, outlook stable
Moody's Ratings (Moody's) affirmed the ratings of Charles River Laboratories International Inc. ("Charles River"). The affirmed ratings include the Ba1 Corporate Family Rating, the Ba1-PD Probability of Default Rating, as well as the Baa3 senior secured ratings, and the Ba2 senior unsecured ratings....
Charles River Laboratories Achieves 100% Renewable Electricity Usage G...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024, significantly ahead of the original target date. In 2020, Charles River became one of the first 300 members of , a global corporate renewable energy initiative, and committed to operating on 100 percent renewable electricity globally by 2030. Today, Charles River joins a small group of leading companies that have achieved this goal organization-wide in accordance with RE10...
Charles River Laboratories Launches Alternative Methods Advancement Pr...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing alternatives to reduce animal testing. The initiative aims to drive the new standard for drug discovery and development and encapsulates the Company’s initial $200 million investment over the past four years and its five-year goal of investing an additional $300 million. This investment spans a portfolio of technology innovations, partnerships, and advocacy efforts to reduce...
Charles River Laboratories Schedules First-Quarter 2024 Earnings Relea...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at . A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharma...
Charles River and Deciphex Launch Patholytix Foresight, a Transformati...
WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in collaboration with Deciphex, an innovator in pathology AI. By combining Deciphex’s unique digital pathology solutions with Charles River’s robust non-clinical pathology programs, clients of both organizations will have access to the technology-driven capabilities to accelerate primary evaluation and peer review in toxicologic pathology assessment, enhancing deci...
Charles River Announces Rare Disease Gene Therapy Collaboration with A...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with . Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure. Ciliopathies are diseases caused by cilia dysfunction, which is a group of complex disorders caused by genetic mutations that result in defective or dy...
Charles River to Perform Plasmid Production for Ship of Theseus
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Ship of Theseus is developing a proprietary suite of biologics based on the HOX family of transcription factors, wh...
Charles River to Perform Plasmid Production for Ship of Theseus
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement. Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate. Ship of Theseus is developing a proprietary suite of biologics based on the HOX family of transcription factors, wh...
Charles River Laboratories Showcases Technology-Driven Capabilities at...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the . Charles River will present technology-driven capabilities and highlight the latest advancements in immuno-oncology, in vitro assays, and more. The meeting is taking place from April 5-10, 2024, at the San Diego Convention Center in San Diego, California. Charles River Launches New Tools & Services to Support Oncology Research Charles River is showcasing an expanding portfolio of end-to-end cancer research tools an...
Charles River Laboratories Publishes 2023 Corporate Citizenship Report
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its , which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet. “The work we do at Charles River today extends beyond science. With more than 21,000 employees, our collective efforts are powerful, and our influence is ...
Charles River Announces Extension of Gene Therapy Manufacturing Allian...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement. NUS Medicine will utilize Charles River’s market leading contract development and manufacturing organization (CDMO) expertise in HQ and GMP- compliant plasmid DNA, which serves as a critical starting material for its engineered stem ce...
Charles River and Navega Therapeutics Announce Comprehensive Gene Ther...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) and , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to established contract development and manufacturing (CDMO) capabilities and advisory services to produce an adeno-associated virus (AAV)-based gene therapy, NT-Z001, for Phase I clinical trials. Developing a Non-Opioid Treatment for Chronic Pain Navega is pursuing...
Charles River Laboratories to Present at Barclays Global Healthcare Co...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at 10:15 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will r...
Charles River Laboratories International Inc: 1 director
A director at Charles River Laboratories International Inc sold 2,750 shares at 261.051USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Charles River and Wheeler Bio Complete Agreement to Accelerate the Jou...
WILMINGTON, Mass. & OKLAHOMA CITY--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls) platform. This new alliance provides early-stage biotechnology companies a unique solution to rapidly transition from pre-clinical activities to first-in-human clinical trials. Combining ...
Charles River Collaborates with Pluristyx, Expanding its Portfolio of ...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with , a leading provider of tools, technologies, and services for the development of cell therapies. The collaboration provides Charles River with broad access to highly characterized and unique stem cell lines, including high-quality embryonic stem (ES) cells and induced pluripotent stem cells (iPSCs) as research tools to support development of new therapeutics. Pluristyx offers a unique product and technology platform in the stem cell biolog...
Charles River Laboratories Announces Fourth Quarter and Full-Year 2023...
WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024. For the quarter, revenue was $1.01 billion, a decrease of 7.9% from $1.10 billion in the fourth quarter of 2022. The impact of foreign currency translation benefited reported revenue by 1.2%, and acquisitions contributed 0.7% to consolidated fourth-quarter revenue. The addition of a 53rd week at the end of 2022, which is periodically required to align to a December 31st calendar year end, reduced r...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PBF PBF ENERGY INC. CLASS A
FFIN FIRST FINANCIAL BANKSHARES INC
CVI CVR ENERGY INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
HTBI HOMETRUST BANCSHARES INC
MOG.A MOOG INC. CLASS A
AXP AMERICAN EXPRESS COMPANY
COF CAPITAL ONE FINANCIAL CORPORATION
ISTR INVESTAR HOLD
PVH PVH CORP.
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
KALV KALVISTA PHARMACEUTICALS
GLOB GAZIT-GLOBE LTD.
AOUT AMERICAN OUTDOOR BRANDS
NKTX INC.
WMG NKARTA
ABNB WARNER MUSIC GROUP CORP. CLASS A
EYPT AIRBNB INC. CLASS A
PSFE EYEPOINT PHARMACEUTICALS
VERA PAYSAFE LTD.
EWTX VERA THERAPEUTICS INC
LBTYA EDGEWISE THERAPEUTICS INC
AEON LIBERTY GLOBAL PLC
AEON BIOPHARMA INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.